TG Therapeutics rises on data for subcutaneous multiple sclerosis drug

TG Therapeutics

03/06/2026 15:01

Updates
** Shares of TG Therapeutics TGTX.O rise 10.1% to $40.30 
** Co says its experimental subcutaneous formulation of multiple sclerosis drug, Briumvi, showed favorable safety and drug exposure in an early-stage study
** Study showed under-the-skin version of the therapy achieved sustained drug levels and was generally well tolerated compared with the approved intravenous formulation - TGTX
** No serious injection-site reactions and no new safety signals were observed, TGTX says
** Briumvi is currently approved in the United States for treating adults with relapsing forms of multiple sclerosis
** Co says a late-stage study comparing subcutaneous and IV Briumvi in patients with relapsing multiple sclerosis has completed enrolment, with results expected in late 2026 or early 2027
** We believe TG's Briumvi has the attractive potential to become the subQ of choice in the CD20 (marker on B cells) market - J.P. Morgan
** Including session moves, stock up 30.6% YTD

 (Reporting by Siddhi Mahatole)
 ((siddhi.mahatole@thomsonreuters.com))